立体定向放射外科治疗特发性舌咽神经痛:一项国际多中心研究
该国际多中心研究纳入22例药物难治性特发性舌咽神经痛患者,评估伽玛刀立体定向放射外科(SRS)的疗效。中位随访45个月,59%患者初始完全缓解,1年、2年、3年、5年、7年维持 adequate 疼痛缓解率分别为63%、49%、38%、38%、28%。结论认为SRS可使55%患者获得持久疼痛缓解,部分患者需追加手术。
要点
- SRS靶点为舌咽神经孔,中位最大剂量80 Gy,59%患者初始完全缓解。
- 维持 adequate 疼痛缓解率1年63%、2年49%、3年38%、5年38%、7年28%。
- 单次SRS后无放射不良反应,重复SRS后2例出现腭舌弓感觉过敏。
核心结论
- 立体定向放射外科可使55%的药物难治性舌咽神经痛患者在1或2次SRS后获得持久疼痛缓解。
- 反应不佳或疼痛复发者可能需要追加SRS、微血管减压术、神经阻滞或神经切断等手术。
- 本研究未观察到SRS后声带功能改变或吞咽障碍。
研究设计与样本
- 国际伽玛刀研究基金会6个参与中心回顾性识别1998年至2015年间接受SRS的22例药物难治性舌咽神经痛患者。
- 患者中位年龄60岁(范围34-83岁),SRS前中位症状持续时间46个月(范围1-240个月)。
- 3例既往手术失败,包括微血管减压术(MVD)(n=2)和球囊压迫(n=1)。
- 放射外科靶点为舌咽神经孔,中位最大剂量80 Gy。
主要发现
- SRS后中位随访45个月(范围6-120个月),12例(55%)随访不足4年。
- 13例(59%)在SRS后中位12天(范围1-60天)达到初始完全疼痛缓解,3例(14%)在中位70天(范围60-90天)达到部分缓解,6例(27%)无疼痛缓解。
- 16例初始疼痛缓解者中,5例维持完全缓解且无需药物(BNI I级),1例维持偶发疼痛缓解且无需药物(BNI II级),3例维持完全缓解但需药物(BNI IIIb级),7例在SRS后中位20个月(范围6-120个月)疼痛复发。
- 维持 adequate 疼痛缓解(BNI I-IIIb级)率:1年63%、2年49%、3年38%、5年38%、7年28%;排除7例随访4年内无复发者后,5年38%、7年28%。
- 10例需追加手术(MVD n=4;重复SRS n=5;舌咽神经阻滞 n=1);5例重复SRS中4例维持疼痛缓解(BNI I级 n=3,BNI IIIb级 n=1)。单次SRS后无放射不良反应;重复SRS后5个月和8个月各1例出现腭舌弓感觉过敏。
临床怎么用
- 作者认为,对于药物难治性舌咽神经痛,SRS可提供持久疼痛缓解。
- 作者指出,反应不佳或疼痛复发者可能需要追加SRS、MVD、神经阻滞或神经切断等手术。
局限性
- 12例(55%)随访不足4年。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE The goal of this study was to evaluate the outcomes of Gamma Knife stereotactic radiosurgery (SRS) when used for patients with intractable idiopathic glossopharyngeal neuralgia. METHODS Six participating centers of the International Gamma Knife Research Foundation identified 22 patients who underwent SRS for intractable glossopharyngeal neuralgia between 1998 and 2015. The median patient age was 60 years (range 34-83 years). The median duration of symptoms before SRS was 46 months (range 1-240 months). Three patients had unsuccessful prior surgical procedures, including microvascular decompression (MVD) (n = 2) and balloon compression (n = 1). The radiosurgical target was the glossopharyngeal meatus. The median maximum dose was 80 Gy. RESULTS The median follow-up was 45 months after SRS (range 6-120 months). Twelve patients (55%) had < 4 years of follow-up. Thirteen patients (59%) had initial complete pain relief at a median of 12 days after SRS (range 1-60 days). Three patients (14%) had partial pain relief at a median of 70 days after SRS (range 60-90 days). Six patients (27%) had no pain relief. Among 16 patients with initial pain relief, 5 maintained complete pain relief without medication (Barrow Neurological Institute [BNI] pain intensity score Grade I), 1 maintained occasional pain relief without medication (BNI Grade II), 3 maintained complete pain relief with medication (BNI Grade IIIb), and 7 patients had pain recurrence at a median of 20 months after SRS (range 6-120 months). The rates of maintenance of adequate pain relief (BNI Grades I-IIIb) were 63% at 1 year, 49% at 2 years, 38% at 3 years, 38% at 5 years, and 28% at 7 years. When 7 patients without pain recurrence within 4 years of follow-up were excluded, the rates of maintenance of adequate pain relief were 38% at 5 years and 28% at 7 years. Ten patients required additional procedures (MVD, n = 4; repeat SRS, n = 5; glossopharyngeal nerve block, n = 1). Four of 5 patients who underwent repeat SRS maintained pain relief (BNI Grade I, n = 3; and BNI Grade IIIb, n = 1). No adverse effects of radiation were observed after a single SRS. Two patients developed hyperesthesia in the palatoglossal arch 5 and 8 months after repeat SRS, respectively. CONCLUSIONS Stereotactic radiosurgery for intractable, medically refractory glossopharyngeal neuralgia provided lasting pain reduction in 55% of patients after 1 or 2 SRS procedures. Patients who had a poor response or pain recurrence may require additional procedures such as repeat SRS, MVD, nerve blocks, or nerve section. No patient developed changes in vocal cord function or swallowing disorders after SRS in this study.
引用
- Kano H, Urgosik D, Liscak R, et al. Stereotactic radiosurgery for idiopathic glossopharyngeal neuralgia: an international multicenter study. J Neurosurg. 2016. PMID: 27903192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。